Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Chelsea Therapeutics to Present at the 25th Annual ROTH Conference



Chelsea Therapeutics to Present at the 25th Annual ROTH Conference

CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25^TH Annual
ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.

Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a
corporate update and an overview of the Northera™ (droxidopa) development
program.

Mr. Oliveto's presentation will be webcast live and archived for 30 days on
Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
www.chelseatherapeutics.com

CONTACT: Investors:
         Fara Berkowitz/Susan Kim
         Argot Partners
         212-600-1902
         fara@argotpartners.com
         susan@argotpartners.com
        
         Media:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Chelsea Therapeutics Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement